vivos therapeutics, inc., a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (sdb) comprising mild-to-moderate obstructive sleep apnea (osa). the company's solutions cover proprietary alternatives for treating mild-to-moderate osa; craniofacial and anatomical anomalies that are associated with mild-to-moderate osa. its treatment for osa involves specially designed and customized oral appliances and treatment protocols. the company, through its vivos integrated healthcare network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate osa. vivos therapeutics, inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals. it caters to general dentists, medical doctors, myofunctional therapists, chiropractors, healthcare providers,
Company profile
Ticker
VVOS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Vivos BioTechnologies, Inc.
SEC CIK
Corporate docs
Subsidiaries
First Vivos, Inc. • BioModeling Solutions, Inc. • Vivos Therapeutics (Canada) Inc. • Vivos Management and Development, LLC • Vivos Del Mar Management, LLC • Vivos Modesto Management, LLC • Vivos Therapeutics DSO LLC • Vivos Airway Alliance, LLC ...
IRS number
813224056
VVOS stock data
Latest filings (excl ownership)
S-1
IPO registration
8 Apr 24
8-K
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Entry into a Material Definitive Agreement
15 Feb 24
EFFECT
Notice of effectiveness
4 Dec 23
424B1
Prospectus with pricing info
1 Dec 23
8-K
Other Events
30 Nov 23
S-1/A
IPO registration (amended)
30 Nov 23
CORRESP
Correspondence with SEC
30 Nov 23
UPLOAD
Letter from SEC
30 Nov 23
Transcripts
VVOS
Earnings call transcript
2023 Q4
28 Mar 24
VVOS
Earnings call transcript
2023 Q3
14 Nov 23
VVOS
Earnings call transcript
2023 Q2
16 Aug 23
VVOS
Earnings call transcript
2023 Q1
8 Jun 23
VVOS
Earnings call transcript
2022 Q4
30 Mar 23
VVOS
Earnings call transcript
2022 Q3
21 Dec 22
VVOS
Earnings call transcript
2022 Q1
17 May 22
VVOS
Earnings call transcript
2021 Q4
1 Apr 22
VVOS
Earnings call transcript
2021 Q3
16 Nov 21
VVOS
Earnings call transcript
2021 Q2
13 Aug 21
Latest ownership filings
SC 13G/A
Huntsman Ronald Kirk
14 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Ronald Kirk Huntsman
20 Jun 23
4
Ronald Kirk Huntsman
20 Jun 23
4
Ronald Kirk Huntsman
15 Jun 23
SC 13G/A
Huntsman Ronald Kirk
10 Feb 23
4
Anja B Krammer
28 Dec 22
4
LEONARD J SOKOLOW
28 Dec 22
4
Matthew Thompson
28 Dec 22
4
Ronald Kirk Huntsman
28 Dec 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 988.00 k | 988.00 k | 988.00 k | 988.00 k | 988.00 k | 988.00 k |
Cash burn (monthly) | 984.67 k | 477.58 k | 1.16 mm | 1.59 mm | 933.33 k | 1.02 mm |
Cash used (since last report) | 6.54 mm | 3.17 mm | 7.72 mm | 10.57 mm | 6.20 mm | 6.75 mm |
Cash remaining | -5.55 mm | -2.18 mm | -6.74 mm | -9.58 mm | -5.21 mm | -5.76 mm |
Runway (months of cash) | -5.6 | -4.6 | -5.8 | -6.0 | -5.6 | -5.7 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 7 |
Closed positions | 8 |
Increased positions | 4 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 2.33 bn |
Total shares | 9.65 mm |
Total puts | 0.00 |
Total calls | 14.20 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Strategic Wealth Designers | 3.22 mm | $1.64 bn |
Gurdev Dave Singh | 3.22 mm | $0.00 |
Ronald Kirk Huntsman | 1.74 mm | $0.00 |
Vanguard | 714.11 k | $364.19 mm |
Geode Capital Management | 201.94 k | $102.99 mm |
Godsey & Gibb Associates | 93.00 k | $47.43 mm |
Two Sigma Investments | 63.30 k | $32.28 mm |
Credit Agricole S A | 59.10 k | $30.14 mm |
VIRT Virtu Financial | 50.85 k | $26.00 k |
STT State Street | 45.65 k | $23.28 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Jun 23 | Ronald Kirk Huntsman | Common Stock | Buy | Acquire P | No | No | 0.53 | 14,000 | 7.42 k | 86,521 |
16 Jun 23 | Ronald Kirk Huntsman | Common Stock | Buy | Acquire P | No | No | 0.53 | 5,000 | 2.65 k | 72,521 |
16 Jun 23 | Ronald Kirk Huntsman | Common Stock | Buy | Acquire P | No | No | 0.54 | 10,000 | 5.40 k | 67,521 |
15 Jun 23 | Ronald Kirk Huntsman | Common Stock | Buy | Acquire P | No | No | 0.5 | 21 | 10.50 | 57,521 |
14 Jun 23 | Ronald Kirk Huntsman | Common Stock | Buy | Acquire P | No | No | 0.49 | 10,000 | 4.90 k | 57,500 |
23 Dec 22 | Ralph Elias Green | Stock Option Common Stock | Grant | Acquire A | No | No | 0.48 | 30,000 | 14.40 k | 76,667 |
23 Dec 22 | Krammer Anja B | Stock Option Common Stock | Grant | Acquire A | No | No | 0.48 | 30,000 | 14.40 k | 76,667 |
News
What's Going On With Vivos Therapeutics Stock?
9 Apr 24
Market-Moving News for April 9th
9 Apr 24
Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
9 Apr 24
Vivos Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application 17/522,740 Titled "Vibrational Oral Appliance With Mandibular Advancements (To Provide Relief From Sleep Disordered Breathing, Sleep Apnea And/Or Snoring)"
4 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
29 Mar 24
Press releases
Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices
9 Apr 24
Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
9 Apr 24
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
28 Mar 24
Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions
12 Feb 24
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
6 Feb 24